Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levonorgestrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 8/20 | 1.00 |
| ▸ | AR | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.71 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levonorgestrel SCHEMBL3916570 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL14360765 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL691861 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Norgestrel SCHEMBL37118 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Norgestrel SCHEMBL4319113 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL825664 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL22364344 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL21741985 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL20927506 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL11697371 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26879 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120009237-B | Preparation method of HOF (fluorescence of fluorescence) ratio fluorescence sensor and application of HOF ratio fluorescence sensor in detection of ammonia gas in expired air of hepatopathy patient | 太原理工大学 | 2026-05-19 | — | — | CN | claimed |
| WO-2026099483-A1 | A READY-TO-USE DRUG DELIVERY SYSTEM | SEVER PHARMA SOLUTIONS (SE) | 2026-05-15 | — | — | WO | claimed |
| EP-4739292-A1 | A THREE-LAYERED INTRAVAGINAL RING | Sever Pharma Solutions (SE) | 2026-05-13 | — | — | EP | claimed |
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | claimed |
| US-12616781-B2 | Tubular nonwoven structure as active agent carrier for the atraumatic treatment of hollow organs, and a process for producing the same | BVS—Best Vascular Solutions GmbH (DE) | 2026-05-05 | — | — | US | claimed |
| US-12616703-B2 | Methods of contraception using nomegestrol acetate and estradiol | Theramex HQ UK Limited (GB) | 2026-05-05 | — | — | US | claimed |
| US-20260115205-A1 | ON DEMAND FEMALE CONTRACEPTIVE | ARCHER DAVID FITZGERALD (US) | 2026-04-30 | — | — | US | claimed |
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| US-12604896-B2 | Mixture of levonogestrel and ethinylestradiol as control for bark insects | NORIEGA VACA ALFREDO ALEJANDRO (MX) | 2026-04-21 | — | — | US | claimed |
| US-20260102341-A1 | Two-Stage Microchip Drug Delivery Device and Methods | DARE MB INC (US) | 2026-04-16 | — | — | US | claimed |
| US-4089952-A | Neuropsychotropic agents and their use | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-05-16 | — | — | US | claimed |
| US-4054651-A | Method of contraception | RICHARDSON-MERRELL INC. (US) | 1977-10-18 | — | — | US | claimed |
| US-4014988-A | Method for treating hypermenorrhea with uterine therapeutic system | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3969502-A | 17-ALPHA ETHYNYLESTRADIOL AND NORGESTREL OR 17-ETHYNYL-19-NORTESTERONE ACETATE | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-07-13 | — | — | US | claimed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | claimed |
| US-3957982-A | AN ESTROGEN AND A PROGESTOGEN | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | claimed |
| US-3942641-A | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-03-09 | — | — | US | claimed |
| US-3939264-A | 17ALPHA-ETHYNYL-ESTRADIOL AND NORGESTROL OR 17ALPHA-ETHYNYL-19-NORTESTERONE ACETATE | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | claimed |
| US-RE28690-E | OVULATION INHIBITION | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | claimed |
| US-3932635-A | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-01-13 | — | — | US | claimed |